BioSpace News Archive

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrion’s international customer base and facilitate entry into new territories.

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.

Sun Pharmaceutical Industries Ltd., “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing essential dermatological conditions, announced the signing of License and Supply Agreements for Winlevi® in the United States and Canada.

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced the closing of its previously announced privately negotiated exchange transactions with certain holders of its 3.500% Convertible Senior Notes due 2026.

uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the second quarter of 2021 and highlighted recent progress across its business.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 4, 2021.

Core One Labs Inc., is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. has commenced the development of another breakthrough psychedelic drug formulation, and confirms the filing of another provisional patent application with the United States Patent and Trademark Office under application number 63147338, for the protection of its intellectual property designed to address Parkinson’s Disease, also known as AKO004.

Leap Therapeutics, Inc. announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 antibody, DKN-01, in combination with tislelizumab, BeiGene’s Ltd.'s anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer, at the European Society for Medical Oncology Congress, being held virtually on September 16-21, 2021.

Acceleron Pharma Inc. announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results.